UNICREDIT BANK/CALL/ABBVIE/160/0.1/18.12.24 Share Price

Warrant

DE000HC61XN3

Real-time BOERSE MUENCHEN 09:10:47 27/06/2024 pm IST
1.5 EUR -12.28% Intraday chart for UNICREDIT BANK/CALL/ABBVIE/160/0.1/18.12.24
Current month+69.31%
1 month+90.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
27/24/27 1.5 -12.28%
26/24/26 1.71 +3.01%
25/24/25 1.66 -6.74%
24/24/24 1.78 +5.95%
21/24/21 1.68 -6.67%

Real-time BOERSE MUENCHEN

Last update June 27, 2024 at 09:10 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ABBVIE INC.
IssuerLogo Issuer UniCredit UniCredit
WKN HC61XN
ISINDE000HC61XN3
Date issued 14/04/2023
Strike 160 $
Maturity 18/12/2024 (174 Days)
Parity 10 : 1
Emission price 2.11
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 2.73
Lowest since issue 0.55
Delta0.67x
Omega 7.035
Premium4.22x
Gearing10.55x
Moneyness 1.056
Difference Strike -8.31 $
Difference Strike %-5.19%
Spread 0.01
Spread %0.67%
Theoretical value 1.525
Implied Volatility 23.07 %
Total Loss Probability 37.11 %
Intrinsic value 0.8836
Present value 0.6414
Break even 176.33 €
Theta-0.02x
Vega0.04x
Rho0.04x

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
-
More about the company

Ratings for AbbVie Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: AbbVie Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
171.2 USD
Average target price
183.2 USD
Spread / Average Target
+7.06%
Consensus